Adcetris for Hodgkin Lymphoma - Details


( Dernière mise à jour : septembre 17, 2013)
Generic Name:
Brentuximab vedotin
État du projet:
Terminé
Domaine thérapeutique:
Hodgkin Lymphoma
Fabricant:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Gamme de produits:
Examen en vue du remboursement

Détails


Strength:
50 mg/vial
Tumour Type:
Lymphoma
Indications:
Hodgkin Lymphoma
Funding Request:
For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates
Review Status:
Complete
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
Funding Request:
For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates
pERC Meeting:
Final Recommendation Issued:

Fichiers

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.